Navigation Links
Diabetes Insight Could Lead to Better Treatments
Date:12/21/2009

Inhibiting a key inflammatory pathway brought powerful results in mice and people, researchers say

MONDAY, Dec. 21 (HealthDay News) -- Scientists have identified a protein that may be involved in the development of type 2 diabetes, a finding that could lead to new drugs to fight this growing worldwide scourge.

This same group of researchers recently showed that inhibiting this pathway worked to block pain associated with gout, an inflammatory condition affecting the joints.

Inflammation also plays a large role in diabetes.

The authors of this study, published online Dec. 21 in Nature Immunology, started their exploration with the NLRP3 inflammasome, which has been linked with different inflammatory diseases.

Inflammasomes are clusters of proteins that stimulate inflammation and play a role in the body's innate immune response, explained Dr. Norma Kenyon, professor at the Diabetes Research Institute of the University of Miami Miller School of Medicine. She is familiar with the new findings.

"The inflammasome sense situations that are dangerous to our body," added study senior author Jurg Tschopp, a professor at the University of Lausanne in Epalinges, Switzerland. "This includes pathogens (bacteria, viruses), but also endogenous 'danger situations,' such as uric acid crystals found in gout, high circulating glucose found in diabetes or beta-amyloid [plaques] found in Alzheimer's disease."

Until now, scientists were unable to figure how out the NLRP3 inflammasome is activated. With that information now in hand, researchers might have another promising route to developing treatments for type 2 diabetes.

The chain of events seems to start with a protein called TXNIP, which, when exposed to oxidative stress, binds to NLRP3 and leads to the production of interleukin-1 beta or IL-1b, an immune system molecule.

IL-1b is also produced by the pancreas' islet cells as a response to high blood sugar. These islet cells are also responsible for secretion of insulin.

To determine if islet production of IL-1b was caused by the interaction of NLRP3 and TXNIP, the researchers exposed islet cells from normal mice and from mice deficient in NLRP3 or TXNIP to high glucose levels. As predicted, the protein-deficient islets made less IL-1b.

What's more, these deficient mice cleared glucose from the bloodstream quicker in response to insulin.

"Our findings predict that type 2 diabetes can be treated by inhibitors of the inflammasome or IL-1b," Tschopp said.

The good news is that these effects of NLRP3 are confined to the insulin-producing beta cells of the pancreas, so compounds to inhibit the pathway should not have systemic effects.

Studies in humans are already under way. According to Tschopp, "clinical studies with type 2 diabetes patients have already been initiated and the first results are again incredibly encouraging. With a single injection of IL-1b inhibitors, glucose levels in diabetes patients are highly reduced during six months. This treatment could replace the standard treatment currently used."'

More information

There's more on type 1 and type 2 diabetes at the American Diabetes Association.



SOURCES: Jurg Tschopp, Ph.D., professor, University of Lausanne, Epalinges, Switzerland; Norma Kenyon, M.D., Martin Kleiman professor of surgery, medicine, microbiology and immunology and biomedical engineering, Diabetes Research Institute, University of Miami Miller School of Medicine; Dec. 21, 2009, online Nature Immunology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Orameds Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
2. UCSF/SFGH project for diabetes patients wins award for innovation, quality
3. SFGH Project for Diabetes Patients Wins Award for Innovation, Quality
4. Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes
5. TrekDesk: A Potentially Positive Impact on Diabetes & Obesity
6. Coffee, Tea Might Stave Off Diabetes
7. UNC scientists coordinate study of link between insulin use and cancer in people with diabetes
8. Study finds over 90 percent of people with gum disease are at risk for diabetes
9. Study shows how gene action may lead to diabetes prevention, cure
10. Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign
11. Chinese-American and Korean-American women at highest risk for diabetes in pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: